Brief: Immuneonco Biopharmaceuticals Shanghai Says Revenue Was RMB74.1 Million For Year
25/03/2025 15:17
March 25 (Reuters) - ImmuneOnco Biopharmaceuticals Shanghai Inc 1541.HK: REVENUE WAS RMB74.1 MILLION FOR YEAR FY LOSS ATTRIBUTABLE RMB315.9 MILLION Further company coverage: 1541.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ImmuneOnco Biopharmaceuticals (Shanghai)
See all newsBrief: Immuneonco Biopharmaceuticals (Shanghai) To Subscribe For Wealth Management Product For Hk$87.5 Million
Brief: ImmuneOnCo Biopharmaceuticals (Shanghai) To Repurchase H Shares In Open Market
Brief: Immuneonco Biopharmaceuticals (Shanghai)Subscribes For Hk$212 Million Wealth Management Product
Brief: Immuneonco Biopharmaceuticals Shanghai Inc Posts FY Loss Attributable RMB218.6 Million
Brief: ImmuneOnco Biopharmaceuticals Shanghai Receives Approval From NMPA China For Investigational New Drug Application Of IMM0306S